Status:
COMPLETED
Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System Blockers
Lead Sponsor:
Yonsei University
Conditions:
IgA Nephropathy
Eligibility:
All Genders
20-70 years
Phase:
NA
Brief Summary
This study will help to show the efficacy of vitamin D and address the optimal strategy to minimize renal injury in IgAN patients.
Eligibility Criteria
Inclusion
- Biopsy-proven Ig AN patients aged 20-70 years
- Patients with residual proteinuria \> 500 mg/g creatinine despite renin-angiotensin system blockade and adequate blood pressure control for more than 3 months
- Patients who give informed consent, and 4) estimated GFR \>= 30 ml/min/1.73 m2.
Exclusion
- patients \< 20 years or \> 70 years
- hypersensitivity to vitamin D analogs
- patients who need urgent dialysis
- hypercalcemia within 3 months (uncorrected serum calcium level \> 10.2 mg/dL)
- clinical features of rapidly progressive glomerulonephritis
- life expectancy less than 24 months
- uncontrolled hypertension
- decompensated liver or lung disease
- symptomatic heart failure (NYHA class II-IV or LVEF \< 40%)
- estimated GFR \< 30 ml/min/1.73 m2.
Key Trial Info
Start Date :
March 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2016
Estimated Enrollment :
168 Patients enrolled
Trial Details
Trial ID
NCT01237028
Start Date
March 1 2011
End Date
August 1 2016
Last Update
September 7 2016
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
National Health Insurance Corporation Ilsan Hospital
Goyang, South Korea, 41-0719
2
Kwandong University Myongji Hospital
Goyang, South Korea, 412-270
3
Wongkwang University Sanbon Medical Center
Gunpo, South Korea, 435-040
4
CHA University Bundang Medical Center
Seongnam, South Korea, 435-040